A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.

The present invention relates to a new formulation of specific nutritional ingredients (nutraceuticals) and/or pharmaceutical compounds.

The present invention relates to a new formulation of specific nutritional ingredients (nutraceuticals) and/or pharmaceutical compounds.

The present invention relates to a new formulation of specific nutritional ingredients (nutraceuticals) and/or pharmaceutical compounds.

The present invention relates to the technical field of medicines. Specifically disclosed is a compound as represented by formula I′, or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, symbols therein being as defined in the claims. The compound of the present invention may be used as a drug for regulating RET kinase activity or treating RET-related diseases, and has good pharmacokinetic properties.

##STR00001##

Compounds, pharmaceutical compositions, and methods are provided herein that may be used to treat cancer, infectious disease, and other conditions associated with ectonucleotide pyrophosphatase pyrophosphatase-phosphodiesterase (ENPP1) dysfunction.

The invention provides a compound of Formula I:

##STR00001##

or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.

The invention provides a compound of Formula I:

##STR00001##

or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.

The subject invention pertains to methods of treating HIV-1 infected subject comprising the administration of growth hormone to a subject infected by HIV-1. The subject may be undergoing co-administration of anti-retroviral therapies (ARTs), may be untreated with anti-retroviral drugs (ARDs) or may be in a period of time where no ART is being administered. Growth hormone may be administered at a fixed dosage for a set period of time or may be administered at a first dosage for a first period of time that may then be increased or decreased to a second dosage for a second period of time.

The subject invention pertains to methods of treating HIV-1 infected subject comprising the administration of growth hormone to a subject infected by HIV-1. The subject may be undergoing co-administration of anti-retroviral therapies (ARTs), may be untreated with anti-retroviral drugs (ARDs) or may be in a period of time where no ART is being administered. Growth hormone may be administered at a fixed dosage for a set period of time or may be administered at a first dosage for a first period of time that may then be increased or decreased to a second dosage for a second period of time.